Breaking News

BioVaxys Acquires IP, Immunotherapeutics Platform Technology & Assets of IMV Inc.

Anticipates tremendous commercial potential with the DPX antigen delivery platform.

Author Image

By: Charlie Sternberg

Associate Editor

BioVaxys Technology Corp. has acquired the entire portfolio of discovery, preclinical and clinical development stage assets in oncology, infectious disease, antigen desensitization, and other immunological fields based on the DPX immune educating platform technology, developed by Canadian biotechnology company, IMV Inc., Immunovaccine Technologies Inc., and IMV USA (IMV).   BioVaxys acquired the extensive technology portfolio from HIMV, LLC, an acquisition vehicle formed by Horizon Technology ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters